The $1,086-a-month number that shows up first in most Zepbound searches is real, but it's also close to the worst-case price. It's what a pharmacy would charge someone with no insurance and no manufacturer program applied. Very few uninsured patients actually pay that, because Eli Lilly sells Zepbound directly to cash-paying patients at a fraction of the retail number.
This guide walks through what uninsured patients actually pay in 2026 — by dose, by program — plus the Medicare and insurance options that exist alongside self-pay. If you're also comparing this against other GLP-1 costs, our drug price checker and manufacturer savings card guide can help you see the full landscape, and our Zepbound Savings Card vs LillyDirect comparison breaks down the insured vs. uninsured path in more depth.
Table of Contents
- List Price vs What You Actually Pay
- LillyDirect Self-Pay Pricing by Dose
- Full Cost Comparison Table
- Eligibility Comparison
- Income Limit Comparison
- Covered Uses Comparison
- How to Get LillyDirect Self-Pay Pricing, Step by Step
- Approval and Shipping Timelines
- Renewal and Ongoing Pricing
- Common Mistakes That Cost You More
- Decision Tree: What Should You Do?
- Practical Examples
- Pros and Cons of Each Path
- Frequently Asked Questions
List Price vs What You Actually Pay
Understanding the gap between "list price" and "real price" is the single most useful thing to know before comparing where to fill Zepbound.
| Price Type | What It Means | Approximate Amount |
|---|---|---|
| List price (WAC) | The manufacturer's published price before any discount | ~$1,086/month (KwikPen, any dose) |
| Standard retail cash price | What a typical pharmacy charges an uninsured walk-in with no program applied | ~$900–$1,086/month |
| LillyDirect self-pay | Eli Lilly's direct-to-patient cash price | ~$299–$449/month, by dose |
Why the gap is so large: List price reflects what would be billed before manufacturer rebates and discounts negotiated through insurance. Since uninsured patients have no insurer negotiating on their behalf, Eli Lilly built LillyDirect specifically to offer a direct, lower cash price instead — which is why shopping through LillyDirect almost always beats a standard retail cash price.
LillyDirect Self-Pay Pricing by Dose
Zepbound's LillyDirect pricing is tiered at the lower doses, then flattens out — a structure that's worth understanding before you titrate up.
| Dose | Approximate Monthly Price (LillyDirect) |
|---|---|
| 2.5 mg (starting dose) | ~$299 |
| 5 mg | ~$399 |
| 7.5 mg | ~$449 |
| 10 mg | ~$449 |
| 12.5 mg | ~$449 |
| 15 mg (maximum dose) | ~$449 |
Tip: Unlike some GLP-1 self-pay pricing that keeps climbing at every dose increase, LillyDirect caps Zepbound at $449/month once you reach 7.5 mg. That means your cost stays flat even if your prescriber increases your dose all the way to the 15 mg maximum.
Full Cost Comparison Table
Here's how every realistic payment path compares side by side, from most to least expensive.
| Path | Approximate Monthly Cost | Who It's For |
|---|---|---|
| Retail cash price, no program | ~$900–$1,086 | Anyone — but rarely the best option |
| LillyDirect self-pay, 2.5–5 mg | ~$299–$399 | Uninsured patients starting treatment |
| LillyDirect self-pay, 7.5–15 mg | ~$449 flat | Uninsured patients at maintenance dose |
| Commercial insurance + Zepbound Savings Card | ~$25 (if plan covers Zepbound) | Insured patients with Zepbound coverage |
| Medicare GLP-1 Bridge (from July 1, 2026) | ~$50 | Eligible Medicare Part D beneficiaries |
Prices shift often. LillyDirect's self-pay tiers, the savings card's terms, and retail cash pricing have all changed more than once during 2026. Treat these figures as a planning guide and confirm the current amount directly at lillydirect.lilly.com before you commit to a specific pharmacy or program.
Eligibility Comparison
| Program | Insurance Required? | Prescription Required? |
|---|---|---|
| LillyDirect self-pay | No | Yes |
| Zepbound Savings Card | Yes — commercial only | Yes |
| Medicare GLP-1 Bridge | Yes — Medicare Part D | Yes |
| Standard Medicare Part D coverage | Yes — for obstructive sleep apnea only | Yes, with appropriate diagnosis |
Income Limit Comparison
None of Zepbound's main cost-reduction paths use income as a qualifying factor — an important, often-missed distinction from Lilly's charity-based programs for other medications.
| Program | Income Limit |
|---|---|
| LillyDirect self-pay | None |
| Zepbound Savings Card | None |
| Lilly Cares Foundation (income-based PAP) | Not applicable — Zepbound isn't covered by this program |
| Medicaid (in states that cover GLP-1s for obesity) | Yes — varies by state |
Important: Zepbound is not included in the Lilly Cares Foundation's free, income-based Patient Assistance Program as of 2026. That program currently covers select other Lilly medications, but not Zepbound. If you need a truly free option based on financial need, Zepbound specifically isn't eligible for it — LillyDirect self-pay is the lowest-cost manufacturer path available.
Covered Uses Comparison
Zepbound is FDA-approved for more than one use, and that distinction matters for insurance and Medicare coverage.
| Indication | Medicare Coverage | Commercial Insurance Coverage |
|---|---|---|
| Chronic weight management | Not covered by Medicare Part D | Varies widely by plan; often requires prior authorization |
| Moderate-to-severe obstructive sleep apnea (with obesity) | Can be covered by Medicare Part D | Generally covered, subject to plan rules |
If your plan requires prior authorization before covering Zepbound for either indication, our prior authorization guide explains what that process typically involves.
How to Get LillyDirect Self-Pay Pricing, Step by Step
Get a valid Zepbound prescription
This can come from your existing doctor or through a licensed LillyDirect-affiliated telehealth provider if you don't have a prescriber already.
Create a LillyDirect account
Register at lillydirect.lilly.com and select the self-pay purchase option for Zepbound.
Choose vial or KwikPen
Both formats sit in the same LillyDirect price range — the decision mostly comes down to your comfort administering each device.
Confirm your dose-specific price before ordering
Pricing is tiered up to 5 mg, then flattens at $449/month from 7.5 mg onward. Confirm the exact current price for your specific prescribed dose before completing checkout.
Complete payment and shipping
No insurance information is required. Enter payment details and confirm your shipping address for home delivery, or pick up at a participating pharmacy.
Approval and Shipping Timelines
| Step | Typical Timeframe |
|---|---|
| LillyDirect account setup | Immediate to same-day |
| Prescription verification | Same-day to a few business days |
| First shipment or pharmacy pickup | A few business days after order confirmation |
| Commercial insurance prior authorization (if applicable) | Several days, plan-dependent |
Renewal and Ongoing Pricing
- LillyDirect self-pay pricing is ongoing month to month as long as you keep reordering — there's no annual renewal requirement like an insurance-based savings card.
- If your dose changes during titration, confirm the new price tier applies at your next order, since pricing depends on dose strength up through 5 mg.
- If you switch to commercial insurance that covers Zepbound, you can transition to the Zepbound Savings Card instead of continuing self-pay.
- If you age into Medicare, LillyDirect self-pay remains available to you, since it doesn't exclude Medicare beneficiaries the way the commercial savings card does.
Unlike commercial savings cards, which typically expire annually and require reactivation, LillyDirect self-pay pricing doesn't have a similar renewal deadline — but the specific price tiers themselves can change during the year, so it's worth checking current pricing periodically rather than assuming an earlier quote still applies.
Common Mistakes That Cost You More
- Filling at a standard retail pharmacy without checking LillyDirect's self-pay price first, ending up paying two to three times more than necessary.
- Assuming Zepbound qualifies for the Lilly Cares free Patient Assistance Program — it currently doesn't.
- Trying to use the Zepbound Savings Card without qualifying commercial insurance behind it.
- Assuming price keeps rising indefinitely at higher doses, when LillyDirect actually caps at $449/month from 7.5 mg onward.
- Assuming Medicare covers Zepbound for weight loss when it currently only covers the separate obstructive sleep apnea indication, plus the newer Bridge program.
- Purchasing compounded tirzepatide from an unverified source without confirming its current legal standing and safety oversight.
The single most expensive mistake is simply not checking LillyDirect pricing before filling elsewhere. The gap between a standard retail cash price and LillyDirect's self-pay price can be $600 a month or more for the same medication.
Decision Tree: What Should You Do?
Step 1: Do you have commercial insurance that covers Zepbound?
✔ Yes → Use the Zepbound Savings Card for the lowest possible copay.
✖ No → Continue to Step 2.
Step 2: Are you on Medicare?
✔ Yes → Check whether you qualify for coverage under the obstructive sleep apnea indication, or ask your Part D plan about the Medicare GLP-1 Bridge.
✖ No → Continue to Step 3.
Step 3: Are you uninsured?
✔ Yes → Use LillyDirect self-pay pricing — expect $299–$399/month while titrating, flattening to $449/month at higher maintenance doses.
Practical Examples
Example 1 — Uninsured, new patient: An uninsured patient starts Zepbound through LillyDirect at the $299/month 2.5 mg starter dose, moving to $399/month at 5 mg, then leveling off at $449/month once they reach their 10 mg maintenance dose — with no further increase even after titrating up to 15 mg.
Example 2 — Insured, plan covers Zepbound: A patient with employer insurance has their plan approve Zepbound after prior authorization. They activate the Zepbound Savings Card and pay around $25/month.
Example 3 — Medicare beneficiary: A Medicare Part D enrollee with a diagnosed obstructive sleep apnea condition and obesity gets Zepbound covered under that specific FDA-approved indication, paying their plan's standard Part D cost-sharing rather than a self-pay price.
Pros and Cons of Each Path
LillyDirect Self-Pay
- No insurance or income verification required
- Dramatically cheaper than standard retail cash pricing
- Price caps at $449/month regardless of how high your maintenance dose goes
- Still hundreds of dollars a month, unlike the free Patient Assistance Program available for some other Lilly medications
- Requires an account setup and ongoing self-management of orders
Zepbound Savings Card (Insured)
- Lowest possible price of all the options, often around $25/month
- No income verification needed
- Requires commercial insurance that already covers Zepbound
- Doesn't help if your plan denies coverage or you're uninsured
Bottom Line
If you're uninsured, the $1,086 retail price shouldn't be your starting assumption — LillyDirect's self-pay pricing brings the real cost down to a fraction of that, and it caps out at $449/month even at the highest maintenance dose. If you have commercial insurance that covers Zepbound, the savings card gets you even lower. Medicare beneficiaries have narrower options, but the sleep apnea indication and the new GLP-1 Bridge program are both worth checking before assuming Zepbound is out of reach.
Whichever path applies to you, confirm the current price directly before committing — this is one of the fastest-moving pricing categories in prescription drugs right now.
Want to see your actual price before you commit?
Compare LillyDirect self-pay pricing, your insurance copay, and other savings options side by side.
Compare Prices Now → Savings Card vs LillyDirect GuideFrequently Asked Questions
Zepbound's retail list price is about $1,086 per month for the KwikPen regardless of dose, but through LillyDirect, Eli Lilly's self-pay channel, uninsured patients can pay as little as $299/month for the 2.5 mg starting dose, $399/month for 5 mg, and a flat $449/month for every dose from 7.5 mg through 15 mg.
Yes, but only up to a point. LillyDirect charges $299/month for the 2.5 mg starter dose and $399/month for 5 mg. From 7.5 mg through the maximum 15 mg dose, the price is capped at a flat $449/month, so your cost doesn't keep climbing as you reach higher maintenance doses.
Medicare Part D does not cover Zepbound for weight loss alone, but it can cover Zepbound when prescribed for its FDA-approved obstructive sleep apnea indication. Separately, starting July 1, 2026, eligible Medicare Part D beneficiaries can access the Zepbound KwikPen for about $50/month through the Medicare GLP-1 Bridge program, subject to plan participation.
No. As of 2026, Zepbound is not included in the Lilly Cares Foundation's income-based, free medication program. Uninsured patients seeking a lower price should use LillyDirect self-pay pricing instead, since it isn't based on income.
No. The Zepbound Savings Card is a copay assistance card for people with commercial insurance that already covers Zepbound — it reduces an existing copay rather than replacing insurance entirely. If you're uninsured, LillyDirect self-pay pricing is the option built for your situation instead.
Compounded tirzepatide is sometimes advertised at a lower monthly price, but its legal availability narrowed significantly after the FDA resolved the national tirzepatide shortage in 2025, since compounding is only broadly permitted during an active drug shortage or for individual patients with a specific documented medical need. Talk to your prescriber about whether a compounded product is appropriate and legally available to you before assuming it's a straightforward cost-saving option.
Zepbound and Mounjaro both contain tirzepatide and are made by Eli Lilly, but Zepbound is FDA-approved for chronic weight management while Mounjaro is approved for type 2 diabetes. They are priced and covered separately by insurance, since plans evaluate them under different formulary categories despite sharing the same active ingredient.
Usually not. Discount coupon services like GoodRx generally apply to the higher retail cash price, which typically still lands well above LillyDirect's direct self-pay pricing. Compare both before filling, but expect LillyDirect to come out ahead in most cases for uninsured patients.
It depends on your state. A limited number of state Medicaid programs cover GLP-1 medications like Zepbound for obesity treatment, while most do not. Check with your state Medicaid program directly to confirm current coverage rules where you live.
If your commercial plan denies coverage, the Zepbound Savings Card's standard tier won't apply since it requires existing coverage to reduce. In that case, compare LillyDirect self-pay pricing while your prescriber pursues an appeal or prior authorization request on your behalf.
How We Researched This Guide
References
- LillyDirect. Zepbound Self-Pay Pricing and Purchase Options.
- Eli Lilly and Company. Zepbound Savings Card Terms and Eligibility.
- U.S. Food & Drug Administration. Tirzepatide Products, Approved Indications, and Compounding Guidance.
- Medicare.gov. Prescription Drug Coverage and GLP-1 Access Guidance.
- Centers for Medicare & Medicaid Services. Medicare Part D Coverage Guidance.
Related Resources
Related Zepbound & Savings Guides
- Zepbound Savings Card vs LillyDirect: Which Saves You More?
- Manufacturer Savings Cards: How They Work
- Patient Assistance Programs: Full Directory
- Drug Price Checker: Compare Costs Instantly
- Medicare Part D: Complete Coverage Guide
- Extra Help (LIS): Medicare Part D Low-Income Subsidy
- GoodRx vs Inside Rx: Which Saves You More?
- Express Scripts Prior Authorization Requirements
Editorial Policy: Refill Relay content is researched using publicly available manufacturer materials, federal guidance, and standard industry pricing practices. Every article is reviewed for clarity, accuracy and usefulness before publication. Pricing and program terms change periodically — confirm current amounts at Eli Lilly's official LillyDirect and Zepbound sites before enrolling. This content is educational and is not medical advice.